Your session is about to expire
What is Remodulin
TreprostinilThe Generic name of this drug
Treatment SummaryTreprostinil is a drug that mimics the effects of prostacyclin, a natural substance that helps regulate blood pressure. It is used to treat pulmonary hypertension, a condition characterized by abnormally high blood pressure in the arteries of the lungs.
Remodulinis the brand name
Remodulin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Remodulin
Treprostinil
2002
47
Effectiveness
How Remodulin Affects PatientsTreprostinil relaxes the blood vessels in the lungs and body, and stops platelets from clumping together. In animals, this leads to a decrease in the amount of pressure in the heart and an increase in how much blood it pumps. Treprostinil can also cause a decrease in heart rate and contraction, although no major effects on heart rhythm have been found. Taking treprostinil increases the risk of bleeding, and can cause symptoms like low blood pressure. People with asthma, COPD, or bronchial hyperreactivity may experience bronchospasms when inhaling treprostinil.
How Remodulin works in the bodyTreprostinil is a medication used to treat pulmonary arterial hypertension. It works by opening potassium channels on cells and increasing levels of a molecule called cAMP, which both stimulates vasodilation in the arteries and prevents platelet aggregation. It also has anti-inflammatory properties.
When to interrupt dosage
The prescribed dosage of Remodulin depends upon the established condition, including refractory to traditional therapy, Pulmonary Arterial Hypertension and NYHA class IV. The measure of dosage deviates, depending on the method of delivery (e.g. Solution or Inhalant) specified in the table below.Condition
Dosage
Administration
NYHA Functional Class III
2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg
, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Tablet, extended release - Oral, Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit
Pulmonary Arterial Hypertension
2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg
, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Tablet, extended release - Oral, Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit
Pulmonary Hypertension
2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg
, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Tablet, extended release - Oral, Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit
refractory to conventional therapy
2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg
, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Tablet, extended release - Oral, Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit
NYHA class IV
2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg
, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Tablet, extended release - Oral, Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit
Warnings
Remodulin ContraindicationsCondition
Risk Level
Notes
Severe Hepatic Impairment
Do Not Combine
Common Remodulin Drug Interactions
Drug Name
Risk Level
Description
Amifostine
Major
Treprostinil may increase the hypotensive activities of Amifostine.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Treprostinil.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Treprostinil.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Treprostinil.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Treprostinil.
Remodulin Toxicity & Overdose RiskSymptoms of a treprostinil overdose can include flushing, headache, nausea, vomiting, diarrhea, low blood pressure, and seizures. Two cases of serious hemodynamic issues have been reported, one of which involved a child who received an accidental dose of 7.5 mg. In animal studies, treprostinil did not increase cancer risk, affect fertility or mating performance, or cause mutagenic or clastogenic effects. Additionally, no significant increases in tumors were found in rats given up to 10 mg/kg/day of oral treprostinil diolamine.
Remodulin Novel Uses: Which Conditions Have a Clinical Trial Featuring Remodulin?
54 active clinical trials are currently investigating the potential of Remodulin to mitigate Pulmonary Arterial Hypertension, NYHA Functional Class III and Pulmonary Arterial Hypertension.Condition
Clinical Trials
Trial Phases
NYHA Functional Class III
0 Actively Recruiting
refractory to conventional therapy
0 Actively Recruiting
Pulmonary Hypertension
25 Actively Recruiting
Phase 2, Phase 3, Phase 1, Phase 4, Not Applicable, Early Phase 1
NYHA class IV
0 Actively Recruiting
Pulmonary Arterial Hypertension
5 Actively Recruiting
Phase 1, Not Applicable, Phase 2
Remodulin Reviews: What are patients saying about Remodulin?
5Patient Review
2/17/2016 Remodulin unfortunately caused me some heart trouble in the form of arythmia. My cardiologist has since taken me off the medication. In addition to that, I experienced awful pain in my face and legs while taking it.
5Patient Review
8/4/2009 Even though there are some less-than-ideal side effects, this medication has really worked well for me.
4.3Patient Review
4/30/2016 I've been using this treatment since July and I'm feeling much healthier now. The initial pain was uncomfortable, but it's worth it for the results. I'm hoping to switch to the pill form soon - has anyone else done that?
4Patient Review
8/12/2009 Remodulin has been a total lifesaver for me. I started using it in 2007 and have had few side effects--(just a little diarrhea and leg pain.) Once you get used to the process, it is simple to use and even easier once you are stable and can use the smaller pump. It is wonderful to be able to breathe again!
3Patient Review
6/13/2010 This drug has been a godsend for our daughter. When she was first diagnosed with PAH, the prognosis wasn't good. We were told that she might only have six to ten months left. Thanks to this medication, she's still here and going strong nearly five years later.
3Patient Review
6/19/2010 At first, this medication is quite painful. However, after using it for three years, I've found that the pain decreases significantly. I hope this helps others who are considering this treatment!
2.7Patient Review
8/18/2010 As I increased my dosage, I found that this medication caused more pain in my extremities. Sometimes the pain was almost unbearable, despite also taking Gabapentin and a strong pain medication.
1.7Patient Review
1/10/2013 The pain at the site is unbearable. I usually have to change the site after just six days because the pain is so intense.
1Patient Review
1/7/2011 I've been on remodulin for 1 1/2 yrs site pain is painful up to 2 wks ,nausia at times. pain in legs & hands.It has lowered right venticle pressure from 110 down to 61,so ikeep doing it and try to stay positive! Good luck to all .Geno
Patient Q&A Section about remodulin
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What type of medication is Remodulin?
"Remodulin is a medication used to treat pulmonary arterial hypertension, which is high blood pressure in the arteries of your lungs. Remodulin can reduce symptoms associated with exercise."
Answered by AI
What is the drug Remodulin used for?
"This helps to decrease the number of hospital visits and improve your ability to exercise.
This medication is used to treat pulmonary arterial hypertension, a type of high blood pressure in the lungs. Treprostinil helps to improve symptoms such as shortness of breath and tiredness. This helps to decrease the number of hospital visits and improve your ability to exercise."
Answered by AI
What happens if you stop Remodulin?
"If you stop taking treprostinil suddenly, or if you decrease your dose too quickly, you may experience symptoms of pulmonary hypertension such as pain when breathing, dizziness, weakness, and fatigue."
Answered by AI
Is Remodulin a continuous infusion?
"Remodulin may be diluted with either 5% Dextrose Injection or 0.9% Sodium Chloride Injection, USP to a total volume not to exceed 20 mL.
Remodulin is a medication that is indicated to be given as a continuous infusion through either a subcutaneous line or an intravenous line. Remodulin is typically given through a subcutaneous line, but can be given intravenously if the subcutaneous route is not tolerated because of severe site pain or reaction. Remodulin can be diluted with either 5% Dextrose Injection or 0.9% Sodium Chloride Injection, USP to a total volume not to exceed 20 mL."
Answered by AI